Terns Pharmaceuticals (TERN)
(Delayed Data from NSDQ)
$5.67 USD
-0.41 (-6.74%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $5.67 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
TERN 5.67 -0.41(-6.74%)
Will TERN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TERN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TERN
Down -39.83% in 4 Weeks, Here's Why Terns Pharmaceuticals (TERN) Looks Ripe for a Turnaround
Down -31.41% in 4 Weeks, Here's Why You Should You Buy the Dip in Terns Pharmaceuticals (TERN)
TERN: What are Zacks experts saying now?
Zacks Private Portfolio Services
All You Need to Know About Terns Pharmaceuticals (TERN) Rating Upgrade to Buy
Biotech Stock Roundup: TERN, SMMT Stocks Surge on Study Data, GSK's Vaccine Study Fails & More
Terns Stock Soars on Positive Data From Phase I Study of Obesity Drug
Other News for TERN
Terns Pharma (TERN) Projects Financial Stability Until 2028 with Ongoing Trials
Terns Pharmaceuticals GAAP EPS of -$0.26 beats by $0.03
Terns Pharmaceuticals reports Q2 EPS (26c), consensus (29c)
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule ...
Commit To Buy Terns Pharmaceuticals At $3, Earn 23.3% Using Options